Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has increased its fiscal 2027 revenue and profit forecasts, buoyed by robust demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, up from an earlier projection of 6.75% to 7.25%. The lower end of its adjusted per share profit forecast has also been raised to $5.94 from $5.90, while the upper end remains at $6.

Strategic Investments and Market Expansion

In a strategic move, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, gaining rights to distribute a robotic surgical device in select markets outside the United States. CEO Geoff Martha highlighted the potential of Cornerstone's Sentire device, which complements Medtronic's existing Hugo system. Martha noted that the penetration of soft tissue robotic surgery in emerging markets is currently under 1%.

Strong Performance Across Business Segments

The company reported a 19.5% increase in sales within its cardiovascular segment, reaching $3.93 billion. This growth was largely driven by its pulsed field ablation portfolio, which saw an impressive 88% growth. During a post-earnings call, Martha emphasized the broad performance across Medtronic's businesses and contributions from newer growth platforms as key factors in their optimistic outlook.

Financial Results Surpass Expectations

Medtronic's quarterly results exceeded market expectations, with an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion. This surpassed analysts' estimates of $1.39 per share on $9.55 billion in revenue, according to data from LSEG. The company's financial chief, Thierry Pieton, mentioned that tariff refunds nearly offset the duties paid during the quarter, although future refunds are not accounted for in the current outlook.